Veracyte reports Q4 adjusted EPS 36c, consensus 26c

Reports Q4 revenue $118.6M, consensus $116.69M. “I’m incredibly proud of what our team accomplished in 2024,” said Marc Stapley, Veracyte’s (VCYT) chief executive officer. “We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant opportunities for Decipher and Afirma to impact more patients and drive growth for Veracyte. We are focused on moving forward with our exciting portfolio of strategic growth drivers while maintaining the financial discipline that has been core to our success.”